CARMEL, Ind., Nov. 2, 2023 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare company addressing some of healthcare's most significant challenges in behavioral and mental health, digital health, and population health, shared its experience at The Nasdaq Stock Market Opening Bell-Ringing Ceremony on Wednesday, November 1, in New York City.
"The sound of the NASDAQ bell resonated with our promise to continually push the boundaries of mental health solutions, explore new frontiers in digital health, and remain dedicated to our pursuit of a healthier population," said Sandeep Allam, Executive Chairman and President, Syra Health.
"Syra Health is a beacon of innovation, dedication, and the transformation of healthcare," said Dr. Deepika Vuppalanchi, CEO, Syra Health. "Syra means perfection and drives us to push boundaries, implement the highest standards, and envision healthcare solutions that were once deemed unattainable."
Nasdaq Livestream
The Company presentation is available for viewing on its corporate website at www.syrahealth.com.
ABOUT SYRA HEALTH CORP.
Syra Health is a healthcare company addressing some of healthcare's most significant challenges. Syra Health specializes in behavioral and mental health, digital health, and population health. Syra Health's solutions are centered on prevention, improved access, and affordable care. For more information, please visit www.syrahealth.com.
For more information, please contact:
For Media Inquiries:
Christine Drury
Communications and Marketing Director
Syra Health Corp.
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.
For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$0.07 |
| Daily Volume: | 0 |
| Market Cap: | US$794K |
February 18, 2025 December 02, 2024 November 26, 2024 | |

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load